The bleeding disorder ITP is becoming a model of immunopathophysiology and treatment in para-/postinflammatory and autoimmune phenomena, clinical aspects, mechanisms of action of new biologic therapeutics and patient's management. The speakers will give an update the physiology of megakaryocytes and their involvement in ITP, demonstrate the possible influences on the various disturbances of the immune response by biologic drugs (IVIG, Anti-D, Anti CD-20 and others) and discuss the stimulation of thrombopoiesis by thrombopoietin receptor agonists in children susceptible for ITP. The third speaker will focus on improvement of diagnosis in the heterogeneous manifestations and natural courses of ITP. A summary of the results of the prospective intercontinental registries, proposals of bleeding scores and quality of life tools to improve the management of patients in regards to the risk of bleeding, the adverse effects, quality of life and general health costs of ITP will be presented and discussed.